Clinical trials: Cardiovascular Disease Other
Functional Mitral Regurgitation, Heart Failure
Mitral Loop Cerclage(MLC) for Reducing Functional Mitral Regurgitation
To evaluate safety and feasibility of Mitral Loop Cerclage(MLC) Annuloplasty with CSTV for repair of functional mitral regurgitation.
- Trial name
- NCT02471664
- Testing
- Mitral Loop Cerclage Annuloplasty
- Where
- 2 sites in United States, South Korea
- Volunteers
- 5 people
- Sponsor
- Tau-MEDICAL Co., Ltd.
Persistent Atrial Fibrillation
The Study for Evaluate of Safety and Efficacy of Vein of Marshall RF Ablation
The goal of this clinical trial is to evaluate the initial safety and effectiveness of an investigational medical device. Electrode catheter ablation of the Marshall vein is performed using TIRA, a clinical trial medical device…
- Trial name
- NCT05854238
- Testing
- TIRA-VoM
- Where
- 2 sites in South Korea
- Volunteers
- 4 people
- Sponsor
- Tau-MEDICAL Co., Ltd.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Multiple Myeloma
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
- Trial name
- MajesTEC-2 (NCT04722146)
- Testing
- Teclistamab, Daratumumab, Pomalidomide
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Hypertension
PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg
PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular…
- Trial name
- NCT00936208
- Where
- 120 sites in Egypt, Saudi Arabia and 1 more
- Volunteers
- 3,184 people
- Sponsor
- Boehringer Ingelheim
Hypertension
26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
The primary objective of this trial is to assess the efficacy and safety of the fixed dose combinations telmisartan 40mg/amlodipine 10mg (T40/A10) or telmisartan 80mg/amlodipine 10mg (T80/A10) during open-label treatment for at…
- Trial name
- NCT00624052
- Testing
- fixed-dose combination of telmisartan 40mg+amlodipine 10mg, fixed-dose combination of telmisartan 80mg+amlodipine10mg
- Where
- 92 sites in Australia, Austria and 10 more
- Volunteers
- 838 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, High Blood Pressure
BVA-200 vs BVA-100 Validation Study
The proposed study is a prospective, observational, investigator and patient blinded study comparing the results of blood volume measurement using the FDA-cleared Daxor BVA-100 device to the Daxor BVA-200 device.
- Conditions
- Heart Failure, High Blood Pressure, High Cholesterol, Anemia
- Trial name
- NCT06227819
- Testing
- BVA-200
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Daxor Corporation
Multiple Myeloma
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with…
- Trial name
- EVOLUTION (NCT00507442)
- Testing
- VELCADE (bortezomib), dexamethasone, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 158 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Abdominal Aortic Aneurysm
Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
The objective of this post-market trial is to evaluate Endologix AFX endovascular AAA system with anatomical fixation against other approved Endovascular systems with proximal fixation.
- Trial name
- LEOPARD (NCT02407457)
- Testing
- AFX EVAR AAA Graft System, FDA Approved EVAR AAA Graft Systems
- Where
- 56 sites in United States
- Volunteers
- 455 people
- Sponsor
- Endologix
Acute Coronary Syndrome
MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial
This study will be a proof-of-concept, placebo-controlled, double-blind, randomized trial in participants with a recent acute coronary syndrome (ACS) to evaluate the efficacy, pharmacokinetics, safety, tolerability, disease…
- Trial name
- PILOT (NCT02678923)
- Testing
- MDCO-216
- Where
- 20 sites in Canada, Czechia and 3 more
- Volunteers
- 126 people
- Sponsor
- The Medicines Company
Acute Stroke
Cytoflavin in Combination With Reperfusion in Stroke Patients
Evaluation of the efficacy and safety of Cytoflavin®, solution for intravenous administration, (OOO NTFF POLYSAN, Russia) for 10 days, patients with cerebral infarction who receive reperfusion therapy, with the start of treatment…
- Trial name
- NCT05297851
- Testing
- Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin), Control
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Non-small Cell Lung Cancer, Head and Neck Cancer
A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China
This is a Phase 1/2a, open-label, multi-center study of JAB-3068 in Patients with advanced solid tumors.This study has two phases: dose escalation phase and dose expansion phase.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03565003
- Testing
- JAB-3068
- Where
- 4 sites in China
- Volunteers
- 126 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Primary Ciliary Dyskinesia (PCD)
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
- Trial name
- NCT06633757
- Testing
- RCT1100
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 14 people
- Sponsor
- ReCode Therapeutics
Hypertension, Pulmonary
Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
The aim of the study is to assess safety, tolerability and clinical effects of different doses of riociguat in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and who are not satisfactorily treated…
- Trial name
- EAS (NCT01784562)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 102 sites in United States, Austria and 18 more
- Sponsor
- Bayer
Type 2 Diabetes Mellitus
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
- Trial name
- SAVOR- TIMI 53 (NCT01107886)
- Testing
- Saxagliptin
- Where
- 536 sites in United States, Argentina and 25 more
- Volunteers
- 18,206 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary…
- Trial name
- EUROMAX (NCT01087723)
- Testing
- Bivalirudin, Heparin
- Where
- 145 sites in Austria, Czechia and 7 more
- Volunteers
- 2,198 people
- Sponsor
- The Medicines Company
Heart Failure, Dyspnea
Evaluation of the Effectiveness of the Cardiostory Device in Distinguishing Heart Failure From Other Causes in Patients Presenting With Dyspnea.
This is a prospective, observational study conducted in the emergency department. Adult patients presenting with dyspnea will be enrolled, and study data will be collected from routine clinical assessments, including medical…
- Trial name
- CARDIOSTORY TN (NCT07685106)
- Testing
- Non invasive cardiac assessment with the CardioStory device
- Where
- 2 sites in Tunisia
- Volunteers
- 850 people
- Sponsor
- CardioStory INC
Dyslipidemia, Coronary Heart Disease
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
The purpose of this study is to evaluate the effectiveness of first-line treatment using Niaspan (an extended release version of niacin) and statins versus other drugs that lower lipid levels, in subjects with elevated fat levels…
- Conditions
- Dyslipidemia, Coronary Heart Disease, Atherosclerosis, Stroke
- Trial name
- NCT00079638
- Testing
- Niacin, Atorvastatin, Simvastatin
- Volunteers
- 300 people
- Sponsor
- Kos Pharmaceuticals
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
- Trial name
- NCT04988555
- Testing
- Enzomenib, azoles, Venetoclax
- Where
- 104 sites in United States, Belgium and 10 more
- Volunteers
- 606 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone
The purpose of this study is to assess the cardiovascular safety of paliperidone in patients with schizophrenia or schizoaffective disorder, with particular attention to the length of the QT/QTc interval, to measure and review…
- Trial name
- NCT00791349
- Testing
- Immediate release (IR) Paliperidone
- Volunteers
- 141 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.